Showing 2181-2190 of 5623 results for "".
- GenSight Biologics Confirms Sustained Efficacy and Safety of Lumevoq Injections 4 Years After One-Time Administrationhttps://modernod.com/news/gensight-biologics-confirms-sustained-efficacy-and-safety-of-lumevoq-injections-4-years-after-one-time-administration/2482174/GenSight Biologics reported initial efficacy and safety results at 4 years post-treatment administration in the REFLECT phase 3 clinical trial with Lumevoq (GS010; lenadogene nolparvovec). The results show that 4 years after a one-ti
- Research: AI Has Perfect Detection Rate for Severe Cases of Retinopathy of Prematurity (ROP)https://modernod.com/news/research-ai-has-perfect-detection-rate-for-severe-cases-of-retinopathy-of-prematurity-rop/2482153/New research from Oregon Health & Science University (OHSU) and collaborators reveal that artificial intelligence technology can accurately and independently detect 100% of severe cases of retinopathy of prematurity (ROP). The research was
- New Study Shows Eylea HD with Extended 12- or 16-Week Dosing Demonstrated Noninferior Vision Gains to Standard of Care Eyleahttps://modernod.com/news/lancet-study-eylea-hd-with-extended-12-or-16-week-dosing-demonstrated-noninferior-vision-gains-to-standard-of-care-eylea/2482151/Regeneron announced The Lancet published 1-year results from the pivotal PULSAR and
- Phase 1b/2a Trial of Exonate's Eye Drop Demonstrates Safety and Biological Activity in Treatment of DR and DMEhttps://modernod.com/news/phase-1b2a-trial-of-exonates-eye-drop-demonstrate-safety-and-biological-activity-in-treatment-of-dr-and-dme/2482148/UK-based Exonate announced data from a phase 1b/2a trial for lead candidate EXN407 demonstrating safety and tolerability of the drug candidate, as well as clear indications of biological activity, according to a company news release. The data position the company for further development
- Sandoz Closes Deal to Acquire Ranibizumab Biosimilar Cimerli from Coherushttps://modernod.com/news/sandoz-closes-deal-to-acquire-ranibizumab-biosimilar-cimerli-from-coherus/2482144/Sandoz has completed the acquisition of the US biosimilar Cimerli (ranibizumab-eqrn) from Coherus BioSciences. In January, in a move to pay down debt and focus on its oncology business, Coherus BioSciences entered into an agreement to divest its Cimerli (ranibiz
- Nicox Names New CEO; Restructures Debt to Focus on NCX 470 Pivotal Trialhttps://modernod.com/news/nicox-names-new-ceo-restructures-debt-to-focus-on-ncx-470-pivotal-trial/2482137/Nicox announced this week that its Board of Directors has promoted Gavin Spencer to Chief Executive Officer. He previously served as Executive Vice-President, Chief Business Officer & Head of Corporate Development. Mr. Gavin will be replacing Andreas Segerros, whose mandat
- Optos Celebrates Milestones: 25,000 Devices Installed Globally and Extensive Clinical Publications Achievedhttps://modernod.com/news/optos-celebrates-milestones-25000-devices-installed-globally-and-extensive-clinical-publications-achieved/2482131/Optos announced a dual milestone achievement of over 25,000 devices installed worldwide, and the collection of 2,500 clinical and peer-reviewed studies spanning 235 disease states, acccording to a company news release. "This remarkable double milestone reflects the unwavering
- SightGlass Vision Receives FDA Breakthrough Device Designation for Myopia Spectacle Lenshttps://modernod.com/news/sightglass-vision-receives-fda-breakthrough-device-designation/2482118/The FDA has granted Breakthrough Device designation to SightGlass Vision's Diffusion Optics Technology (DOT) spectacle lenses, which are intended to slow myopia progression in children. The design is the first to use the contrast management mechanism of action, incorporating thousan
- FDA Gives Green Light to Okyo Pharma for Clinical Trial Design for OK-101 in Neuropathic Corneal Painhttps://modernod.com/news/fda-gives-green-light-to-okyo-pharma-for-clinical-trial-design-for-ok-101-in-neuropathic-corneal-pain/2482109/Okyo Pharma announced that the FDA has cleared OK-101 as its first investigational new drug (IND) application for the treatment of Neuropathic Corneal Pain (NCP). The initial IND submission to FDA proposed an open-label design for the clinical trial. Based on positiv
- New Spiral-Shaped Lens Designed to Improve Vision at Range of Distances and Lighting Conditionshttps://modernod.com/news/new-spiral-shaped-lens-designed-to-improve-vision-at-a-range-of-distances/2482108/French researchers have developed a spiral-shaped lens that is designed to maintain clear focus at different distances in varying light conditions. Published in the journal Optica,1 the researchers say the lens works much like progressive lenses used f